Cellectis S.A. (CLLS) vs ImmuCell Corporation (ICCC)
- Cellectis S.A. CLLS 1.26 +0.80%
- ImmuCell Corporation ICCC 9.65 −1.03%
Cellectis S.A. and ImmuCell Corporation are both Biotechnology companies. Cellectis S.A. and ImmuCell Corporation are of similar size ($90.4M and $88.6M). Cellectis S.A. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 114×. ImmuCell Corporation grew revenue faster over the last twelve months: 8.49% against 0.61%. ImmuCell Corporation has the higher net margin (2.57% vs −102.3%) and the higher return on invested capital (7.84% vs 0.00%). Across the 18 metrics below, ImmuCell Corporation leads on 15 and Cellectis S.A. on 3.
Valuation
Profitability
| Metric | CLLS | ICCC | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 40.32% | 65.16% |
| Operating margin | (90.88%) | 12.60% | 0.00% |
| Net margin | (102.34%) | 2.57% | 0.00% |
| Free cash flow margin | (68.63%) | 13.79% | 0.00% |
| Return on equity | (94.54%) | 2.57% | (56.66%) |
| Return on assets | (21.02%) | 1.69% | (49.22%) |
| Return on invested capital | 0.00% | 7.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack